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Abstract (108 words) 
In stark contrast to the treatment of drug-sensitive TB, the evidence base underpinning global 
guidelines for the treatment of MDR-TB is very poor. This, with the lack of experience from previous 
trials and the nature of the disease, means that there are a number of methodological aspects that 
are particular to trials of new regimens for MDR-TB. These aspects include the weight of evidence 
required to change policy and practice, the flexibility to make adaptations to an ongoing trial, the 
choice of patient population, the importance of the internal control, the duration and frequency of 
follow-up, and particular safety monitoring for novel combinations of new and repurposed drugs.  
 
Introduction 
The recommendations from the WHO guidelines for the treatment of TB that new patients with 
pulmonary drug-sensitive TB (DS-TB) should receive the daily 6 month regimen 2HRZE/4HR are 
considered strong recommendations based on the highest grade of evidence(1). 
In striking contrast,  prior to the phase II trials of bedaquiline(2) and delamanid(3) and others 
currently ongoing (see www.resisttb.org/?page_id=1602), there have been no late stage randomised 
controlled trials for the treatment of multi-drug resistant TB (MDR-TB).  The recommendations that 
relate to both the composition and duration of MDR-TB treatment regimens are based on the lowest 
quality of evidence (on a 4 point scale)(4). The primary source of evidence underpinning these 
guidelines is a meta-analysis consisting entirely of observational studies, most of which employed 
individualised treatment thereby suffering from a potential for bias by indication(5). Evidence for the 
efficacy of the WHO recommended regimen under programme conditions is limited; of the 
estimated 480,000 people who developed MDR-TB in 2013, only 111,000 (23%) were started on 
treatment with an expected treatment success rate of only 50%(6).  
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The poor evidence base, the lack of experience from previous trials, and the nature of the disease 
mean that there are a number of methodological aspects that are particular to trials of new 
regimens for MDR-TB. 
Weight of evidence required to change policy and practice 
Since the current WHO guidelines for the treatment of MDR-TB are based on ‘very low quality 
evidence’(4), it is likely that considerably weaker evidence would be required to change policy and 
practice as compared to what would be required to change that for the treatment of DS-TB. This is 
evidenced by the uptake in some settings of variants of the 9-month Bangladesh regimen(7) based 
only on one observational study from a single country(8). 
Investigators have a responsibility to current and future MDR-TB patients to deliver a trial to the 
highest standards of design, conduct and analysis. Nevertheless, it may be justifiable to make 
concessions in certain areas in order to speed regimen evaluation, taking into consideration 
regulatory requirements for any future licensing applications.  Concessions might include the use of 
more novel trial designs, or an acceptance that the family-wise type I error rate (the chance of any 
false positive result among multiple intervention arms) may exceed 5% in a multi-arm trial(9). In the 
context of limited effective treatment options for MDR-TB, a type II error (a false negative result) 
would be disastrous. Investigators should therefore be careful that study power is not compromised.  
Trial adaptations 
Due to the large number of planned trials and an even larger number of observational studies that 
will be conducted in the new few years, trials should be designed to be flexible enough to adapt to 
external data. Trials should include multiple intervention arms to maximise the chance of finding an 
effective regimen(10). Trials do not necessary need to have adaptive designs (although such designs 
are often more efficient(11)), but investigators should be aware of other studies that are ongoing  
that have a bearing on their study (perhaps because of similar drugs being studied) and be ready to 
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consider modifications to treatment arms, eligibility or trial design as necessary. This awareness can 
be achieved through familiarity with the research community and what is presented at TB 
conferences, but also clinical trial registries and the list of ongoing MDR-TB trials curated at 
www.resisttb.org. An example of a successful adaptation is the addition of two arms containing 
bedaquiline in the STREAM trial (ClinicalTrials.gov Identifier: NCT02409290). 
Patient population 
As with any trial, the primary objective(s) of the trial will directly determine the patient population 
to be enrolled in trial. The MDR-TB patient population is, in general, more heterogeneous than the 
DS-TB patient population and eligibility criteria should therefore not be too restrictive so as to 
ensure the broadest possible generalizability. The decision to include patients with XDR- and pre-
XDR- TB will depend on the trial objectives. In many settings, rifampicin mono-resistant TB is 
managed in the same way as MDR-TB and consideration should be given to also including these 
patients in a trial. Patients co-infected with HIV should be included as should those on antiretroviral 
therapy, with as few restrictions on antiretroviral regimens as possible. However, there are many 
settings where there is limited HIV-TB co-infection where an improved MDR-TB regimen would be of 
great benefit even if it cannot be given with certain antiretroviral regimens (only 12% of all new TB 
cases in 2014 were HIV positive(6)). 
Inclusion of individuals from other special populations in MDR-TB trials is encouraged to increase 
generalizability; children and pregnant women have historically been seriously under-represented in 
TB trials(12, 13). Broader eligibility criteria will have implications for algorithms for the management 
of adverse events, processes for informed consent (for children and others unable to give consent), 
the potential for drug-drug interactions with concomitant medications, inclusion of additional 
stratification factors at randomisation, and variability in treatment outcomes which may require an 
increase in sample size.  
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Internal and external controls 
Apart from a few well researched settings, since there are little available data on the performance of 
currently used regimens, any clinical trial should include an internal control. This is in contrast to an 
uncontrolled study where the comparison is made against an external control either in similar 
patients outside the study or against some sort of historical control. Absence of any internal control 
is “treacherous”(14) as any benefits seen might be due to secular trends or patient selection leading 
to false inference about the benefits of an intervention. This would result in an ineffective or 
dangerous treatment being given to patients, and any future research being undermined because of 
a bogus ‘standard of care’. Some have advocated for uncontrolled trials for new treatments for 
Ebola virus disease(15), although the dangers have been well-articulated(16). There is, however, an 
important role for uncontrolled trials in more untreatable forms of MDR-TB (such as the NiX-TB trial, 
ClinicalTrials.gov NCT02333799) where the available treatment options and prognosis is not 
dissimilar to Ebola, but these should be considered exploratory or ‘hypothesis generating’ to be 
followed by randomised controlled trials to generate robust, unbiased evidence.  
Choice of control 
The WHO guidelines are implemented slightly differently in different settings and there is therefore 
no such thing as a universal standard of care regimen. Due to the paucity of evidence, what is 
standard of care in one setting may be considered to be inappropriate in another setting due to a 
perception of inferior efficacy or safety. As new drugs are introduced and new evidence emerges 
from other trials and observational studies, it is highly likely that international guidelines will change 
during the 5 or more years that a clinical trial usually takes to complete.  
The choice of control will therefore depend on the objectives of the trial and could be the locally 
used implementation of the WHO guidelines, or a variant of the 9-month ‘Bangladesh regimen’ (for 
which there is growing observational data (7, 17)), or another alternative. Use of an internal control 
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that is inferior to the standard of care is likely to result in an unreliable over-estimate of the efficacy 
of the intervention regimen. Investigators should consider what impact changing guidelines have on 
the management of patients within the trial, and also on how the results will be received when the 
trial is completed.  
Duration and frequency of follow-up 
It is known that the majority of relapses occur within six months of stopping treatment in clinical 
trials of DS-TB(18, 19) and results from REMoxTB(20), RIFAQUIN(21) and OFLOTUB(22) have 
confirmed this. Some groups are therefore designing clinical trials in DS-TB with the primary 
endpoint 12 months after randomisation (i.e. 6 months after the longest duration regimen being 
studied).  
There are very limited data on the timing of relapse in clinical trials of short-course regimens for the 
treatment of MDR-TB. Nevertheless, it is probably reasonable to select the primary endpoint for a 
clinical trial in MDR-TB to be 6-9 months after the longest duration regimen being studied, although 
crucial to continue to follow-up for a minimum of 18 months post-randomisation for a definitive 
evaluation of the regimens being studied. A secondary analysis at the time of the primary analysis 
could be useful to confirm that long-term results are consistent in the subgroup of patients for 
whom the longer follow-up data is available. 
Total duration and frequency of follow-up will depend in part on expected toxicities and 
pharmacokinetic properties of the drugs being studied. As in DS-TB, for trials of regimens of different 
durations, the primary endpoint should be at a fixed time from randomisation, rather than from end 
of treatment, since this is an endpoint that is most relevant to the patient when they are enrolled 
into the trial. Core research definitions for treatment outcomes in adult drug-resistant TB trials have 
recently been proposed(23). 
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Safety Monitoring 
Treatment for MDR-TB is a risk-benefit balance between the poorly understood efficacies and 
toxicities of various second-line drugs. This is somewhat different to DS-TB where the drugs have, for 
the most part, well-established safety profiles. Any more intensive safety monitoring should be done 
on patients on all arms so as to avoid biased reporting of adverse events. A central expert clinical 
team can be useful to (A) provide the best support for patient management to sites as needed, but 
also (B) to encourage consistent decision-making regarding complex treatment changes due to 
toxicity and treatment failure between study sites and treatment arms. 
Conclusion 
Compared with the extensive experience within many groups of conducting trials to evaluate new 
regimens for the treatment of DS-TB, there is almost no experience of conducting trials to evaluate 
new regimens for the treatment of MDR-TB. A better understanding will come with more 
experience, and included here are some methodological considerations in the design and conduct of 
trials for new regimens for MDR-TB.  
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